NCT04715529已完成1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation and Food Effect Study to Assess the Safety, Tolerance, and Pharmacokinetics of FZJ-003 In Healthy Volunteers
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2021年1月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability
研究概览
简要总结
A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of FZJ-003, an oral Janus kinase1 (JAK1) inhibitor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Written informed consent；
- •Communicate well with the researcher and be able to complete the research in accordance with the research regulations；
- •No plan for pregnancy in the next 6 months and voluntarily take effective contraceptive measures; No plan for sperm or egg donation；
- •Healthy male and/or female subjects between the ages of 18 and 50 years ( inclusive)；
- •Male body weight≥50.0kg or female body weight≥45.0kg; Body Mass Index (BMI) between 18 to 28 (both inclusive), calculated as weight in kg / height in m2.
排除标准
- •Someone smoking more than 5 pieces per day within the 3 months before the trial；
- •Suspected of being allergic to investigational drug or any ingredient in the investigational drug, or people with allergies (multi-drug or food allergies)；
- •Having a history of alcohol abuse (14 units of alcohol per week: 1 units = beer 285 mL, or 25 mL of spirits, or 100 mL of wine);
- •Blood donation or extensive blood loss ≥400 mL within 3 months before screening, or planning blood donors during the study;
- •Urine drug test positive or have a history of drug abuse or drug use in the past 5 years;
- •Subjects who were intolerant of high-fat meals (2 boiled eggs, 1 slices of buttered bacon toast, a box of fries, and a glass of whole milk) were applied only to subjects who participated in the postprandial test;
- •Taked any drug within 14 days before screening, including prescription drugs, over-the-counter drugs, Chinese herbal medicines and health products (except regular supplementary vitamins);
- •Taked any drug that changes liver drug enzyme activity within 28 days before screening, such as CYP3A4 inhibitors or inducers;
- •Major changes in diet or exercise habits within 2 weeks before screening or during the period from screening to administration;
- •Took a special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, and other activities that affect drug absorption, distribution, metabolism, excretion and so on within 2 weeks before screening;
- •Received or planned to receive any vaccine within 30 days before and after the trial;
- •Participated in clinical trials within 3 months before the first administration of the study, or planned to participate in other clinical trials during the study period;
- •Having difficulty of swallowing or any history of gastrointestinal diseases that affect drug absorption;
- •With low immune function or immunodeficiency, or long-term use of immunosuppressive drugs; or used immunosuppressive drugs within 30 days before screeing;
- •Have or have had malignant tumors；
- •Active tuberculosis; or have a history of tuberculosis or latent tuberculosis infection; tuberculosis infection T cell spot test positive;
- •Any infection that has been determined to be clinically significant by the investigator within 3 months or any infection within 7 days before the study;
- •Herpes or varicella within 3 months before the trial;
- •Underwent major trauma or major surgery in 3 months before screening, or have plan for surgery in trial;
- •Have a history of diverticulitis, peptic ulcer or perforation of digestive tract；
- •Clinical laboratory tests are abnormal and have clinical significance, or other clinical findings showing clinically significant diseases (including but not limited to heart Cerebrovascular, gastrointestinal, lungs, endocrine, renal, nerves, blood, immunizations, or mental disease);
- •Active viral hepatitis (B or C) as demonstrated by positive serology at Screening；or test positive for human immunodeficiency virus (HIV) at Screening; or syphilis treponema pallidum antibody and syphilis rapid plasma reagin test are positive;
- •QTcB interval greater than (>) 470 (male) or 480 (female) milliseconds;
- •Female subjects are in lactation or serum pregnancy test are positive during screening or during the test;
- •Acute illness or combination therapy from the screening stage to administration;
- •Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior to the use of the study drug;
- •Taking any alcoholic products within 24 hours prior to the use of the study drug, or cannot limit alcohol drinks as required in trial;
- •Other circumstances that is deemed not appropriate for the trial.
研究组 & 干预措施
FZJ-003
Experimental
干预措施: FZJ-003 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability
时间窗: up to 72 hours postdose
Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; ECG testing). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study.
次要结局
- Area under the plasma concentration-time curve (AUC)(up to 72 hours postdose)
- Maximum Plasma Concentration (Cmax)(up to 72 hours postdose)
- Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK-dependent biomarkers(up to 24 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Tolerance, Pharmacokinetics of Jaktinib in Healthy VolunteersHealthy VolunteersNCT03314402Suzhou Zelgen Biopharmaceuticals Co.,Ltd126
已完成
1 期
A Phase I Study in Healthy ParticipantsHealthy ParticipantsNCT06277167Kexing Biopharm Co., Ltd.35
已完成
1 期
Single Dose Study of SHR4640 in Healthy SubjectsHyperuricemia GoutNCT02815839Jiangsu HengRui Medicine Co., Ltd.50
Unknown
1 期
Study of OsrhAAT or Placebo in Healthy VolunteersEmphysema Secondary to Congenital AATDNCT05315921Healthgen Biotechnology Corp.48
已完成
1 期
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.Healthy VolunteersNCT05628116PHARMENTERPRISES LLC38